Conestat alfa for the treatment of angioedema attacks

Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Benjamin, Bernstein, Jonathan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132097/
https://www.ncbi.nlm.nih.gov/pubmed/21753889
http://dx.doi.org/10.2147/TCRM.S15544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132097/
https://www.ncbi.nlm.nih.gov/pubmed/21753889
http://dx.doi.org/10.2147/TCRM.S15544

Ejemplares similares